Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume -, Issue -, Pages 1-5
Publisher
Informa UK Limited
Online
2022-01-31
DOI
10.1080/09546634.2022.2036674
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real‐world experience versus clinical trials: pros and cons in psoriasis therapy evaluation
- (2021) Eleonora Cinelli et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison
- (2021) Angelo Ruggiero et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2
- (2021) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Reply to “Psoriasis exacerbation after Covid‐19 vaccination: report of 14 cases from a single center” by Sotiriou E et al.
- (2021) M. Megna et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
- (2021) Tarja Mälkönen et al. ACTA DERMATO-VENEREOLOGICA
- Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
- (2021) A. Ruggiero et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study
- (2021) Angelo Ruggiero et al. Dermatologic Therapy
- Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
- (2021) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Letter to the editor regarding article “Yalici‐Armagan B, Tabak GH, Dogan‐Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID‐19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1–5”
- (2021) Luca Potestio et al. Journal of Cosmetic Dermatology
- New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
- (2021) Matteo Megna et al. Biomedicines
- Guselkumab: Short‐term effectiveness and safety in real clinical practice
- (2020) Lourdes Rodriguez Fernandez‐Freire et al. Dermatologic Therapy
- Effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis under real‐life conditions: a retrospective multicenter study
- (2020) A.‐C. Fougerousse et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience
- (2020) Matteo Megna et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience
- (2020) Claudio Bonifati et al. Dermatologic Therapy
- Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐ interleukin ‐17 treatment: A real‐life 52‐week retrospective study
- (2020) Angelo Ruggiero et al. Dermatologic Therapy
- Psoriasis Pathogenesis and Treatment
- (2019) Adriana Rendon et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
- (2019) Kristian Reich et al. LANCET
- Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial
- (2018) R.G. Langley et al. BRITISH JOURNAL OF DERMATOLOGY
- Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”
- (2018) Matteo Megna et al. CLINICAL RHEUMATOLOGY
- Guselkumab for the treatment of psoriasis
- (2018) Matteo Megna et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions
- (2018) Peter Foley et al. JAMA Dermatology
- Psoriasis and sport: a new ally?
- (2014) N. Balato et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started